Change history 13 February 2024 A Correction to this paper has been published: Abbreviations AE: Adverse event APRI: Aspartate aminotransferase to platelet ratio biw: Twice weekly bpm: Beats per min DG: Dose group ELF: Enhanced liver fibrosis EoT: End of treatment Fib-4: Fibrosis-4 GCGR: Glucagon receptor GI: Gastrointestinal GIPR: Glucose-dependent insulinotropic polypeptide receptor GLP-1R: Glucagon-like peptide-1 receptor MCPMod: Multiple comparisons procedure with modelling MMRM: Mixed model for repeated measures NAFLD: Non-alcoholic fatty liver disease NASH: Non-alcoholic steatohepatitis PGI-S: Patient Global Impression of Severity qw: Once weekly SMBG: Self-monitoring of blood glucose TEAE: Treatment-emergent adverse event TFEQ-R18 V2: Three-Factor Eating Questionnaire VAS: Visual analogue scale References Pi-Sunyer X, Astrup A, Fujioka K et al (2015) A randomized, controlled trial of 3.0 mg of liraglutide in weight management
Gastroparesis (stomach paralysis) : Symptoms such as persistent bloating, acid reflux, and vomiting undigested food may signal delayed stomach emptying (gastroparesis)
95% CI 1.59, 0.65), metformin (WMD: 1.09
A clinician can talk through what is known, what is unknown, and what is appropriate for you
Biochemical assays have shown strong activation of GIPR with measurable activation of GLP 1R and GCGR, producing a coordinated receptor engagement profile that differs from single receptor agonists such as GLP 1 selective peptides or dual agonists such as GLP 1 and GIP analogs
